OxSonics' SonoTran has the capability to maximise the therapeutic efficacy of unmodified solid tumour cancer drugs. SonoTran exploits a purely mechanical, drug-class-agnostic effect to enhance the dose, distribution and penetration of drugs throughout tumours. Using proprietary ultrasound technology, SonoTran also provides on-screen monitoring of where and when a drug has been delivered in real time.

Latest News
15 April 2016
5 October 2015
© OxSonics Ltd. 2016